Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02906787 · ClinicalTrials.gov registry record · NA
Behavioral Activation for Smoking Cessation and the Prevention of Post-Cessation Weight Gain
A NA study of Smoking Cessation and Weight Loss, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 288
- Enrollment target
- 1
- Study location
NCT02906787: Completed NA study of Smoking Cessation and Weight Loss, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02906787 is a NA study of Smoking Cessation and Weight Loss that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 288 participants, below the 473-participant average among 188 other Smoking Cessation trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02906787, a NA study of Smoking Cessation and Weight Loss, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 288 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to better understand (1) why people gain weight when they quit smoking and (2) whether certain types of smoking cessation (i.e. quit smoking) counseling combined with the nicotine patch help people quit smoking and gain less weight.
Primary Outcome
Smoking abstinence (primary outcome) will be assessed and biochemically verified at the End of Treatment Visit (week 8), at 12 and 26 weeks after the target quit date. The primary smoking outcome variable will be 7-day point prevalence abstinence (no smoking, not even a puff, for at least 7 days prior to the assessment) biochemically verified by CO \< 5 ppm at End of Treatment (week 8), and by saliva cotinine \< 15ng/ml at the 12- and 26-week follow-up.
Conditions Studied
Interventions
- BEHAVIORAL BAS+
- BEHAVIORAL SC
Study Locations (1)
Pennsylvania
- Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2016-09-13 |
| Est. Completion | 2021-02-28 |
| Phase | NA |
What the finished NCT02906787 record still lists
NCT02906787 is an interventional study that assigns participants to a tested intervention. The registered 288 participants enrollment target is mid-sized for trials with a published cap, below the 473-participant average among 188 other Smoking Cessation trials with a reported enrollment target (39% lower).
The record links to 2 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which BAS+ is the first listed.
NCT02906787 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02906787 about?
NCT02906787 is a clinical study titled "Behavioral Activation for Smoking Cessation and the Prevention of Post-Cessation Weight Gain". The purpose of this research study is to better understand (1) why people gain weight when they quit smoking and (2) whether certain types of smoking cessation (i.e. quit smoking) counseling combined with the nicotine patch help people quit smoking and gain less weight.
What is the current status of trial NCT02906787?
This trial is currently completed. It is a NA study. The enrollment target is 288 participants. The study started on 2016-09-13. Estimated completion is 2021-02-28.
What conditions does trial NCT02906787 study?
This clinical trial studies the following conditions: Smoking Cessation, Weight Loss.
What interventions are being tested in trial NCT02906787?
The interventions under investigation include: BAS+ (BEHAVIORAL), SC (BEHAVIORAL).
Who is sponsoring clinical trial NCT02906787?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02906787 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02906787's enrollment target sits among peer trials
288 84th of 188 higher than 104 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy
RECRUITING · NA
-
Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors
RECRUITING · NA
-
ACT Lung Health Intervention: Phase Two
RECRUITING · NA
-
Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network
RECRUITING · NA
-
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
RECRUITING · NA
-
Urban and Reservation Implementation of All Nations Breath of Life
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
- NCT03741777 · 288 participants · NA
Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume
- NCT03937635 · 288 participants · Phase 3
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- NCT04621877 · 288 participants · NA
Lay-Delivered Behavioral Activation in Senior Centers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI